Novo Nordisk’s stocks experienced the sharpest monthly decline since July 2002 due to growing competition and several ...

Barclays has lowered its first-quarter 2025 estimates for Novo Nordisk (CSE:NOVOb) (NYSE:NVO) ahead of its Q1 2025 report, citing weaker-than-expected prescription volumes for key drugs Wegovy and ...

Learn more about whether Jazz Pharmaceuticals plc or Novo Nordisk A/S is a better investment based on AAII's A+ Investor ...

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...

(Reuters) -Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its ...

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment ...

A popular weight-loss drug used by celebrities overseas has been approved by New Zealand’s medicine regulatory body, with its ...

Shares of Hims & Hers Health ( HIMS 5.01%) surged on Tuesday, closing the session up 5.25% after having been up by as much as ...

Shares of the company were up 8.5% in afternoon trading. The telehealth firm is following its peers Teladoc and LifeMD in offering Lilly's Zepbound ahead of restrictions on selling copies known as ...

Drugmakers are lobbying Trump to phase in tariffs on imported pharmaceutical products in hopes of reducing the sting from the ...

In the SOUL trial, Rybelsus produced a 14% risk reduction of major adverse cardiovascular events in patients with type 2 ...

Chronic diseases require a lifetime of long-term follow-up. Randomised controlled trials are considered the most robust ...